The Type 2 diabetes drug Actos has been linked to an increased risk of bladder cancer in patients who took this medication. Actos is produced by Takeda Pharmaceutical Company, a Japanese drug manufacturer that focuses on research and development. The 230-year-old company is one of the world’s leading pharmaceutical developers.
Actos (pioglitazone) hit the shelves in August of 1999, and up until recently was Takeda’s top-selling drug, with sales topping $3 billion in 2010. If you or someone you know used Actos to treat Type 2 diabetes and now suffers from bladder cancer, you might be able to fight for financial compensation. Contact the Actos lawsuit attorneys of Williams Kherkher today by calling 800-641-9810 to learn more about the options open to you at this time.
Actos Recalls in Europe
The French public health insurance office conducted an official three-year study, finding a connection between Actos and bladder cancer. The drug was pulled off French shelves by their drug safety authority in June, 2011. Germany examined the French data and also issued a recall on the drug soon after. The French study found that after a year of Actos use, a person’s chance of developing bladder cancer increases by 40%.
Actos is also sold under the names “Actoplus Met”, “Actoplus Met XR,” and “Duetact.” It is also used in Competact, which is a combination of Actos and metformin, another diabetes drug developed by Takeda.
If you or someone you love has developed bladder cancer after taking Actos to treat Type 2 diabetes, the experienced Actos lawyers of Williams Kherkher may be able to help you secure compensation for treatments and your unnecessary pain and suffering. Contact us today by calling 800-641-9810 and learn more.